FDA approves Lundbeck's intravenous migraine prevention drug Vyepti, to launch in April 2020 Medical Dialogues Bureau23 Feb 2020 6:00 AM GMTDeerfield: Lundbeck announced that VYEPTI™ (eptinezumab-jjmr) has been approved by the U.S. Food and Drug Administration (FDA) for the preventive...
Drugmaker Teva hires Lundbeck CEO Schultz to restore its health Ruby Khatun Khatun12 Sep 2017 4:17 AM GMTJERUSALEM/COPENHAGEN: Teva poached Lundbeck's Kare Schultz as its new chief executive on Monday, handing the drugs industry veteran the urgent task of...